Tetra Bio Pharma Inc
TSX:TBP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Tetra Bio Pharma Inc
Pre-Tax Income
Tetra Bio Pharma Inc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tetra Bio Pharma Inc
TSX:TBP
|
Pre-Tax Income
-CA$39m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-50%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Pre-Tax Income
$367m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
Pre-Tax Income
-CA$326.1m
|
CAGR 3-Years
53%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Pre-Tax Income
-$17.1m
|
CAGR 3-Years
48%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Pre-Tax Income
-$168.1m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
-112%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Pre-Tax Income
-CA$6.7m
|
CAGR 3-Years
47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Tetra Bio Pharma Inc
Glance View
Tetra Bio-Pharma, Inc. engages in the discovery and development of cannabinoid-based drugs and treatments. The company is headquartered in Orleans, Ontario and currently employs 33 full-time employees. The company went IPO on 2008-04-15. The firm is engaged in the development of bio pharmaceuticals and natural health products containing cannabis and other medicinal plant-based elements. The firm is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. The firm's objective is to bring prescription drugs and treatments to relieve symptoms associated with advanced cancer pain, chronic pain, Acute Respiratory Distress Syndrom (ARDS), sepsis and ophthalmic disease. Its products include QIXLEEF, CAUMZ, REDUVO Capsules, REDUVO Adversa, ARDS-003 and PPP-002. Its QIXLEEF is a botanical inhaled drug with a fixed ratio of tetrahydrocannabinol (THC) and cannabidiol (CBD).
See Also
What is Tetra Bio Pharma Inc's Pre-Tax Income?
Pre-Tax Income
-39m
CAD
Based on the financial report for Aug 31, 2022, Tetra Bio Pharma Inc's Pre-Tax Income amounts to -39m CAD.
What is Tetra Bio Pharma Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-50%
Over the last year, the Pre-Tax Income growth was -33%. The average annual Pre-Tax Income growth rates for Tetra Bio Pharma Inc have been -39% over the past three years , -50% over the past five years .
